Short Interest in Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Declines By 9.6%

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 79,800 shares, a decrease of 9.6% from the October 15th total of 88,300 shares. Based on an average daily volume of 23,300 shares, the days-to-cover ratio is presently 3.4 days.

Cipher Pharmaceuticals Price Performance

Shares of Cipher Pharmaceuticals stock opened at $10.29 on Tuesday. Cipher Pharmaceuticals has a 52 week low of $3.99 and a 52 week high of $14.60. The business has a 50 day moving average price of $11.30 and a 200-day moving average price of $9.15.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.